GLP-1 Drugs Linked to Nail and Hair Issues, Study Finds

Individuals taking glucagon-like peptide-1 (GLP-1) medications, such as Ozempic and Mounjaro, are significantly more likely to develop nail disorders, according to a new study presented at the European Academy of Dermatology and Venereology. The research found that users of these drugs were nearly 25% more likely to experience a nail disorder compared to those not on the medications.

A particularly concerning finding was the increased likelihood of nail detachment, where the nail separates from the nail bed. This condition was over four times more prevalent among GLP-1 users, with 39% reporting it compared to 9% of a control group. Once detached, nails cannot be reattached and require several months to over a year to regrow.

Beyond detachment, two-thirds of GLP-1 users reported at least one nail disorder. Nail discoloration also appeared 2.7 times more frequently in those taking the medications.

"Until now, nail changes associated with GLP-1 therapies had essentially been anecdotal," stated study author Charles Taïeb. While weight loss, a common effect of GLP-1s, can contribute to nail problems like brittleness and slower growth due to nutritional deficiencies and dehydration, the study suggests a potential link beyond these factors. Researchers attempted to account for pre-existing dermatological conditions, nutritional deficiencies, and weight loss, yet nail detachment and discoloration remained two to three times more common in GLP-1 users.

"Our findings show a clear association, but they also underline an important point: not everything that happens during GLP-1 treatment is necessarily caused by the treatment itself," Taïeb added.

Hair Loss Also More Prevalent

A companion study involving the same participants revealed a significantly higher incidence of hair loss among GLP-1 users. Unusual hair loss, characterized by noticeable shedding, was reported by 50% of GLP-1 users, compared to 34% in the control group. Loss in hair volume or density was more than twice as common, and scalp redness occurred approximately three times more frequently.

While hair loss on GLP-1s is a known phenomenon, often attributed to rapid weight loss and physical changes, experts generally consider it temporary. However, the authors of this study noted that hair loss was frequently accompanied by itching, redness, or scaling, suggesting an inflammatory component. Scalp inflammation, they indicated, was common and potentially treatable with specialized shampoos and topical medications.

Awareness Over Alarm

The study authors emphasized that these findings are intended for "awareness rather than alarm." They stressed that hair and nail changes are primarily aesthetic and usually temporary, while the health benefits of weight loss achieved with these medications have significant long-term impacts. They advised patients experiencing such changes to consult their doctor rather than discontinuing treatment independently.